<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94021">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01817855</url>
  </required_header>
  <id_info>
    <org_study_id>D2550C00002</org_study_id>
    <nct_id>NCT01817855</nct_id>
  </id_info>
  <brief_title>To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients</brief_title>
  <official_title>A Phase I, Randomized, DoubleBlind Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Inhaled Doses (MAD) of AZD7624 to Healthy Subjects and Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics
      of multiple ascending doses of AZD7624 in healthy subjects and patients with chronic
      obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Randomized, DoubleBlind Placebo-Controlled Study to Investigate the Safety,
      Tolerability and Pharmacokinetics of Multiple Ascending Inhaled Doses (MAD) of AZD7624 to
      Healthy Subjects and Patients with COPD
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change from baseline up to 66 days in safety variables (adverse events, vital signs, body temperature, physical exams, ECGs, telemetry, clinical laboratory safety tests and spirometry).</measure>
    <time_frame>Up to 66 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cohorts 1 and 4: Study duration [from screening visit (Day -42) through follow up visit (up to Day 22) at multiple timepoints up to 64 days] Cohorts 2 and 3: Study duration [from screening visit (Day -42) through follow up visit (up to Day 24) at multiple timepoints up to 66 days]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AZD7624 single dose pharmacokinetics profile from blood in healthy volunteers (cohorts 1, 2 and 3) and COPD patients (cohort 4).</measure>
    <time_frame>Day 1 and 8 (cohort 1), Day 1 and 9 (cohort 2 and 3), Day 1 and 7 (cohort 4): pre-dose, 5, 15 and 30 min, 1, 2, 3, 4, 6, 9, 12, 18 and 24 hrs (and 36, 48 and 72 hrs following dosing Day 1 for cohort 2 and 3)</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters: Cmax, tmax, λz; t1/2, area under the plasma concentration-time curve from zero to 24 hours [AUC(0-24)], from zero to the time of the last measurable concentration [AUC(0-last)] and from zero to infinity (AUC), CL/F and  Vz/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AZD7624 multiple dose pharmacokinetics profile from blood in healthy volunteers (cohorts 1, 2 and 3) and COPD patients (cohort 4).</measure>
    <time_frame>Day 1 and 8 (cohort 1), Day 1 and 9 (cohort 2 and 3), Day 1 and 7 (cohort 4): pre-dose, 5, 15 and 30 min, 1, 2, 3, 4, 6, 9, 12, 18 and 24 hrs (and 36, 48 and 72 hrs following dosing Day 1 for cohort 2 and 3)</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters: Cmax, tmax, Cmin, area under the plasma concentration-time curve from zero to the end of the dosing interval [AUC(0-τ)], CL/F, extent of accumulation on multiple dosing (RCmax and RAUC), and time dependency of the pharmacokinetics.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>COPD</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Groups 1-4 multiple ascending doses of AZD7624 Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.
COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 patients will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Groups 1-4 multiple ascending doses of placebo Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.
COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 will receive matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7624</intervention_name>
    <description>Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg)  inhaled IMP via a nebulizer</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match</intervention_name>
    <description>Multiple doses inhaled placebo via a nebulizer</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects aged 18 to 55 years (inclusive) with suitable
             veins for cannulation or repeated venipuncture.

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

          -  Plasma myoglobin and CK not above the upper reference range of the analysing
             laboratory at Day -1

          -  Male and/or female patients with COPD aged above18 years with suitable veins for
             cannulation or repeated venipuncture.

          -  Clinical diagnosis of COPD for more than 1 year at Visit 1, according to the Global
             Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines

        Exclusion Criteria:

          -  Any clinically important illness, medical/surgical procedure or trauma within 4 weeks
             of the first administration of the IP

          -  Receipt of another new chemical entity (defined as a compound which has not been
             approved for marketing) or participation in any other clinical study that included
             drug treatment within at least 3 months of the first administration of the IP in this
             study

          -  Any clinically important abnormalities in clinical chemistry, haematology or
             urinalysis results as judged by the Investigator

          -  Any positive result on screening for serum hepatitis B surface antigen (HBsAg),
             hepatitis C antibody and human immunodeficiency virus (HIV)

          -  History or presence of gastrointestinal, hepatic or renal disease or any other
             condition known to interfere with absorption, distribution, metabolism or excretion
             of drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saeed Khan, MBBS, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drg Research Centre At Guys Hosipital, 6 Newcomen Street London SE1 1YR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naimish Patel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca, Wilmington, US</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quintiles Drug Research Unit Call Centre</last_name>
    <phone>0800 634 1132</phone>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1,</keyword>
  <keyword>Safety,</keyword>
  <keyword>Tolerability,</keyword>
  <keyword>Healthy,</keyword>
  <keyword>COPD patients</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
